[Clinical efficacy of clarithromycin delayed release dosage form in the treatment of community-acquired pneumonia].
The efficacy of clarithromycin retarded release dosage form in the treatment of patients with community-acquired pneumonia was estimated in a open prospective comparative study. The drug was administered in a dose of 500 mg once a day (29 patients) and in a dose of 500 mg twice a day (28 patients). The clinical efficacy in the compared regimens amounted to 90.6 and 93.3% of the patients respectively and the bacteriological efficacy was 93.3 and 84.6% respectively. The adverse reactions were observed in 15.6 and 30.0% of the cases respectively.
Iutanova
N S
NS
D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D017291:Clarithromycin / Q000008:administration & dosage / Q000627:therapeutic use*; D017714:Community-Acquired Infections / Q000188:drug therapy; D003692:Delayed-Action Preparations; D005260:Female; D006193:Haemophilus influenzae; D006801:Humans; D008297:Male; D008875:Middle Aged; D018410:Pneumonia, Bacterial / Q000188:drug therapy* / Q000382:microbiology; D013211:Staphylococcus aureus; D013296:Streptococcus pneumoniae
D000900:Anti-Bacterial Agents; D003692:Delayed-Action Preparations; D017291:Clarithromycin